| Trial ID: | L3551 |
| Source ID: | NCT00644501
|
| Associated Drug: |
Diapep277
|
| Title: |
Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: DiaPep277
|
| Outcome Measures: |
Primary: Preservation of endogenous insulin secretion/beta-cell function, as measured by mixed-meal tolerance test stimulated C-peptide secretion., every 6 months up to 24 months from T0 | Secondary: improved metabolic control and the insulin dose required to maintain it., every 3 months up to 24 months from T0
|
| Sponsor/Collaborators: |
Sponsor: Andromeda Biotech Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
43
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-09
|
| Completion Date: |
2013-06
|
| Results First Posted: |
|
| Last Update Posted: |
2013-07-11
|
| Locations: |
Wolfson Medical Centre, Holon, 58100, Israel|Diabetic Unit, Hadassah Medical Center, Jerusalem, 91120, Israel|Schneider Children's Medical Centre, Petach Tikva, 49202, Israel
|
| URL: |
https://clinicaltrials.gov/show/NCT00644501
|
